|
AU3210997A
(en)
*
|
1996-05-24 |
1997-12-09 |
University Of Maryland At Baltimore |
Dna vaccines for eliciting a mucosal immune response
|
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
|
NZ503334A
(en)
*
|
1997-09-15 |
2002-05-31 |
Genetic Immunity Llc |
A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell
|
|
JP2002508338A
(ja)
*
|
1997-12-12 |
2002-03-19 |
ナルディニ，ルイジ |
レンチウィルスベクターの治療使用
|
|
WO1999047146A1
(en)
*
|
1998-03-17 |
1999-09-23 |
Julianna Lisziwiewicz |
Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
|
|
US6461616B1
(en)
*
|
2000-09-09 |
2002-10-08 |
Akzo Nobel Nv |
EIAV p26 deletion vaccine and diagnostic
|
|
US20070025958A1
(en)
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
|
CA2950109C
(en)
|
2000-10-27 |
2019-02-19 |
John W. Hadden |
Vaccine immunotherapy for immune suppressed patients
|
|
US7628980B2
(en)
|
2000-11-23 |
2009-12-08 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US7097842B2
(en)
|
2000-11-23 |
2006-08-29 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
|
HU230198B1
(hu)
|
2000-11-23 |
2015-10-28 |
Bavarian Nordic A/S |
Módosított Vacciniavírus Ankara-variáns
|
|
EP1372708B1
(en)
|
2001-02-13 |
2008-06-18 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY |
Vaccine for transcutaneous immunization against travellers' diarrhoea
|
|
EP1456230A2
(en)
|
2001-12-04 |
2004-09-15 |
Bavarian Nordic A/S |
Flavivirus ns1 subunit vaccine
|
|
EP1420822B2
(en)
|
2002-04-19 |
2017-07-05 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
AU2003264144C1
(en)
|
2002-09-05 |
2009-12-17 |
Bavarian Nordic A/S |
Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
|
|
EP1590432A4
(en)
*
|
2003-01-15 |
2008-05-14 |
Res Inst For Genetic And Human |
DNA COMPOSITION AND ITS USE
|
|
FR2872170B1
(fr)
*
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
EP1797189A4
(en)
*
|
2004-09-02 |
2010-05-19 |
Qun Chen |
ENCAPSIDATION SYSTEM FOR THE PRODUCTION OF RECOMBINANT VIRUSELY PARTICLES
|
|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
US8765462B2
(en)
|
2007-05-04 |
2014-07-01 |
University Health Network |
IL-12 immunotherapy for cancer
|
|
WO2009070639A1
(en)
|
2007-11-28 |
2009-06-04 |
Irx Therapeutics, Inc. |
Method of increasing immunological effect
|
|
WO2010009465A2
(en)
*
|
2008-07-18 |
2010-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Htlv-ii vector and methods of use
|
|
AU2010248761B2
(en)
|
2009-05-15 |
2016-02-11 |
Irx Therapeutics, Inc. |
Vaccine immunotherapy
|
|
CN107050430B
(zh)
|
2009-12-08 |
2021-10-15 |
伊尔克斯治疗有限公司 |
逆转朗格汉斯细胞免疫抑制的方法
|